Taipei, Taiwan | February 25, 2026 YC Biotech Co., Ltd. (“YC Biotech”), a leading biotechnology Contract Research Organization (CRO), today announced that it has entered into a Master Strategic Alliance Agreement with YD Bio USA, Inc. (“YD Bio USA”), a subsidiary of Nasdaq-listed biotechnology company YD Bio Limited (Nasdaq: YDES). This partnership marks the establishment […]
Taipei, Taiwan | January 19, 2026 YC Biotech announced today that its strategic partner, JY-Biomed, has received official notification from the U.S. Food and Drug Administration (FDA) regarding the Investigational New Drug (IND) application for Stemis™ (IND 32415). The FDA has cleared the IND, allowing the clinical trial to proceed. Following this significant regulatory greenlight, YC Biotech will assist JY-Biomed in leveraging this US clearance
Taipei, Taiwan | January 09, 2006 YC Biotech announced today that it has successfully assisted its partner, SL Bio, in reaching regulatory alignment with the U.S. FDA regarding the development pathway for CTA-001, following a productive INTERACT meeting (Meeting ID: 22044). This engagement provided key expert guidance from the Agency, significantly accelerating the program’s transition toward clinical development. CTA-001 consists of autologous T cells expanded
Taipei, Taiwan | December 15, 2025 YC Biotech announced today that it has successfully assisted its strategic partner, JY-Biomed, in completing a formal regulatory engagement with the U.S. FDA regarding the IND development strategy for ExoVeris™ (Meeting ID: 22002). Through this Pre-IND meeting, the companies have obtained clear regulatory guidance on clinical, CMC (Chemistry, Manufacturing, and Controls), and non-clinical study designs, setting a definitive
Taipei, Taiwan | September 18, 2025 Taiwanese biotech teams continue to strengthen their presence in the international regenerative medicine arena. YC Biotech Co., Ltd. and JY Biomed Co., Ltd. recently submitted a Pre-Investigational New Drug (Pre-IND) meeting request to the U.S. Food and Drug Administration (FDA) for ExoVeris™, advancing the product toward clinical development. ExoVeris™
Taipei, Taiwan | October 23, 2025 YC Biotech Co., Ltd. and JY Biomed Co., Ltd. today announced the formal submission of a Pre-Investigational New Drug (Pre-IND) meeting request to the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) for Stemis™ (Human Umbilical Cord-Derived Mesenchymal Stem Cells, hUC-MSCs). The companies have
[Taipei, Taiwan] – [June 13, 2025] YC Biotech today announced the official launch and ongoing progress of its Alzheimer’s disease stem cell clinical trial, conducted in collaboration with its trusted partner, JY BioMed. This partnership aims to explore the potential of stem cell therapy in slowing the progression of Alzheimer’s disease and improving cognitive function,
[Taipei, Taiwan] – [June 13, 2025] As the global population continues to age, the pursuit of delaying aging and enhancing quality of life remains a constant endeavor. Today, YC Biotech announced that its groundbreaking anti-aging stem cell clinical trial, commissioned by JY BioMed, is actively progressing at Taipei Medical University Hospital. This marks a significant
